Stem Inc (STEM)

[Edward]

View this email in your browser
Good morning traders,

FROM BROAD STREET ALERTS

We have been watching this one for at least 3 years. Everything screams breakout right now- chart, fundamentals and ground breaking biotechnology. Big news just released yesterday and a recent 1 for 12 reverse stock split which greatly reduced the amount of shares in the public float a few days ago. Do not miss out on this one.


StemCells Inc. (NASDAQ: STEM)


In 1999, StemCells scientists were the first to isolate and expand human neural stem cells.

News

StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study

NEWARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, today announced that it will be presenting top line 12-month data from Cohort I of its Pathway™ Study later this month as part of the Company’s first quarter 2016 analyst call. The Company is planning to then release detailed final data on Cohort I at a scientific venue in June. Full Press Release- http://finance.yahoo.com/news/stemcells-inc-report-12-month-140000314.html


Highlights

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS).

The Company’s proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for chronic spinal cord injury (SCI).

Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product.

Driven by more than 20 years of pioneering research and innovation, StemCells, Inc. is the undisputed leader in human neural stem cell research and development.

As the first ever to conduct a U.S. clinical trial with human neural stem cells, StemCells is the only company, to date, with established human safety and preliminary efficacy data for these cells.

The Company’s comprehensive patent portfolio includes seminal technology in cell biology, with neural stem cell patents covering compositions of matter, methods of manufacture and methods of use.

Credited with significant breakthroughs in the field, the StemCells team includes internationally renowned experts in stem cell biology, biotechnology, regenerative medicine and cGMP manufacturing.


Credited with significant breakthroughs in the field, their distinguished team includes internationally renowned experts in the fields of stem cell biology, biotechnology, regenerative medicine and cGMP manufacturing, working alongside their accomplished business leaders to realize the great promise of stem cell technology.



We will be back in the morning with a full profile on STEM.


The Team